NUFORMIX PLC Logo

NUFORMIX PLC

NFX | IL

Overview

Corporate Details

ISIN(s):
GB00BYW79Y38
LEI:
2138003XG3H3I2J3BJ24
Country:
United Kingdom
Address:
6TH FLOOR, EC3V 0HR LONDON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Nuformix PLC is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology. The company's core strategy involves drug repurposing, utilizing its proprietary cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's lead development programs target conditions within oncology supportive care and fibrosis, aiming to create novel treatments from existing medicines.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for NUFORMIX PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-11 08:00
Legal Proceedings Report
US FDA ODD Application Submitted for NXP002
English 13.5 KB
2025-05-29 08:00
Regulatory News Service
Confirmation of European ODD for NXP002
English 13.6 KB
2025-05-28 11:28
Prospectus
Nuformix plc - Single prospectus
English 866.5 KB
2025-05-23 14:19
Prospectus
Prospectus
English 866.5 KB
2025-05-23 14:08
Report Publication Announcement
Publication of a Prospectus
English 13.3 KB
2025-02-28 13:30
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.3 KB
2025-02-14 15:18
Report Publication Announcement
Posting of Annual Report and Notice of AGM
English 8.4 KB
2025-01-30 08:00
Share Issue/Capital Change
£168,750 Placing
English 13.1 KB
2025-01-29 08:00
Annual / Quarterly Financial Statement
Annual Results for period ended 30 September 2024
English 414.7 KB
2025-01-28 08:00
Regulatory News Service
NXP002 ODD Application Submitted
English 11.4 KB
2025-01-13 08:00
Regulatory News Service
NXP002 Orphan Drug Designation Draft Application
English 9.6 KB
2024-11-29 18:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.1 KB
2024-11-05 15:25
Director's Dealing
Director/PDMR Dealings
English 39.9 KB
2024-11-04 11:17
Declaration of Voting Results & Voting Rights Announcements
Result of General Meeting
English 21.2 KB
2024-10-18 11:34
Prospectus
Nuformix plc - Single prospectus
English 1.6 MB

Automate Your Workflow. Get a real-time feed of all NUFORMIX PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for NUFORMIX PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Spago Nanomedical AB Logo
Develops nanomedicine for precision MRI tumor diagnostics and targeted cancer radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Developing first-in-class macrocyclic drugs for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops and out-licenses preclinical cancer drug programs using fragment-based discovery.
Sweden SPRINT
Stayble Therapeutics AB Logo
Develops an injectable therapy for disc-related spinal disorders as an alternative to surgery.
Sweden STABL
Stem Cells Spin Spolka Akcyjna Logo
Commercializes patented MIC-1 stem cell technology for regenerative medicine.
Poland SCS
STRIX GROUP PLC Logo Isle of Man KETL
SynAct Pharma Logo
Developing oral resolution therapies for inflammatory diseases like rheumatoid arthritis.
Sweden SYNACT
SYNAIRGEN PLC Logo
Develops an inhaled interferon beta therapy for severe viral lung infections.
United Kingdom SNG
Terranet B Logo
Develops ultra-fast ADAS anti-collision technology for automakers to protect vulnerable road users.
Sweden TERRNT
Israel TMIS